ABG
RCKT icon

Ally Bridge Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Ally Bridge Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-125,176
Closed -$2.45M – 34
2022
Q4 		$2.45M Sell
125,176
-354,330
-74% -$6.53M 2.38% 19
2022
Q3 		$7.65M Buy
+479,506
New +$7.48M 5.05% 6

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ally Bridge Group's RCKT Position: Q1 2023 in Review

Ally Bridge Group sold out of Rocket Pharmaceuticals (RCKT) in Q1 2023, closing a stake of 125,176 shares — an estimated $2.45M sold.

Ally Bridge Group first reported a position in RCKT in Q3 2022 and held it in 2 quarters. The position peaked at $7.65M in Q3 2022. 163 funds tracked by Wall St. Rank hold RCKT as of Q1 2023.

  • Ally Bridge Group reported no remaining Rocket Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ally Bridge Group sold 125,176 Rocket Pharmaceuticals shares in Q1 2023, an estimated $2.45M.
  • Ally Bridge Group first reported a position in Rocket Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Ally Bridge Group's Rocket Pharmaceuticals position peaked at $7.65M in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.